The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice.

ABSTRACT:

Background

Recent studies in the NOD (non-obese diabetic) mouse model of type 1 diabetes (T1D) support the notion that tyrosine kinase inhibitors have the potential for modulating disease development. However, the therapeutic effects of AG490 on the development of T1D are unknown.

Materials and methods

Female NOD mice were treated with AG490 (i.p, 1 mg/mouse) or DMSO starting at either 4 or 8 week of age, for five consecutive week, then once per week for 5 additional week. Analyses for the development and/or reversal of diabetes, insulitis, adoptive transfer, and other mechanistic studies were performed.

Results

AG490 significantly inhibited the development of T1D (p = 0.02, p = 0.005; at two different time points). Monotherapy of newly diagnosed diabetic NOD mice wit

SUBMITTER: Davoodi-Semiromi A 

PROVIDER: S-EPMC3351395 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature